HRTX

HRTX Total Current Assets

$229.85MQuarterly · USD

Period ending:

HRTX FY Current AssetsUSD
HRTX FY Current Assets1987-12-31: $16.50M1988-12-31: $12.30M1989-12-31: $8.80M1990-12-31: $6.20M1991-12-31: $4.70M1992-12-31: $19.10M1993-12-31: $15.10M1994-12-31: $16.40M1995-12-31: $16.50M1996-12-31: $11.70M1997-12-31: $15.20M1998-12-31: $12.80M1999-12-31: $13.80M2000-12-31: $25.05M2001-12-31: $21.62M2002-12-31: $15.97M2003-12-31: $11.26M2004-12-31: $15.50M2005-12-31: $7.65M2006-12-31: $16.21M2007-12-31: $35.80M2008-12-31: $10.82M2009-12-31: $8.31M2010-12-31: $2.50M2011-12-31: $18.24M2012-12-31: $54.09M2013-12-31: $72.93M2014-12-31: $73.73M2015-12-31: $134.75M2016-12-31: $62.14M2017-12-31: $228.06M2018-12-31: $447.25M2019-12-31: $479.06M2020-12-31: $314.20M2021-12-31: $254.42M2022-12-31: $205.44M2023-12-31: $188.77M2024-12-31: $209.01M2025-12-31: $238.07M$479.06M$0.00
1987-12-312025-12-31

Source: Financial Modeling Prep (FMP). Annual fiscal periods; reported in USD. Dates are period ends; a fiscal year may differ from a calendar year.

HRTX total current assets history

Assets expected to be converted to cash within one year. The available annual fiscal periods series contains 39 observations from Dec 31, 1987 to Dec 31, 2025.

Heron Therapeutics Inc Total Current Assets — Annual fiscal periods (USD)
Period endingTotal Current Assets (USD)
238,066,000
209,014,000
188,774,000
205,435,000
254,423,000
314,196,000
479,064,000
447,248,000
228,063,000
62,143,000
134,751,000
73,732,000
72,925,000
54,090,000
18,240,000
2,501,000
8,313,000
10,816,000
35,796,000
16,206,000
7,648,000
15,496,000
11,258,000
15,974,000
21,623,827
25,049,849
13,800,000
12,800,000
15,200,000
11,700,000
16,500,000
16,400,000
15,100,000
19,100,000
4,700,000
6,200,000
8,800,000
12,300,000
16,500,000

Compare total current assets

All HRTX financial metrics · HRTX stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.